Clinical trial
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681
Study timeline
Study start (actual)2022-10-11Date precision: day
Registry last updated2026-09-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Alzheimer Diseaseunresolved
Agitation,Psychomotorunresolved
Care Giving Burdenunresolved
NPSunresolved
Aggressionunresolved
Interventions
IGC-AD1-ActiveDRUG
IGC-AD1-PlaceboDRUG
Sponsors & collaborators
IGC Pharma, LLClead sponsor
Mapped research locations
MiamiFlorida, United States3DallasTexas, United States2BaltimoreMaryland, United States1St LouisMissouri, United States1TorontoOntario, Canada1TampaFlorida, United States1MontrealQuebec, Canada1Oklahoma CityOklahoma, United States1AustinTexas, United States1RichmondVirginia, United States1ProvidenceRhode Island, United States1HamiltonOntario, Canada1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05543681 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.